ARCHIVES

‘We Cannot Tolerate One Third Reduction In Centers. Prevention, Clinical Trials Programs’

This article is from The Cancer Letter archive.

Vol. 17 No. 36 | September 20, 1991

Download PDF Visit The Full Archive

Related Articles

FDA Approves Erbitux for Head & Neck Cancer.

March 3, 2006

ACCC Members Find Few Answers, Many Problems

February 7, 1975

Simone Retires From Academic Medicine, But Plans To Remain Active In Advisory Roles.

September 7, 2001

FDA Committee Can’t Find “Reasonable” Evidence Alkylating Agent Clinical Use Is Carcinogenic

September 10, 1976

Arzerra Maintenance Therapy Extends PFS In Phase III Trial, Compared to Observation

August 29, 2014

Capitol Hill: Sen. Harkin Introduces NIH Funding Bill That Boosts Budget to $46.2 Billion by 2021

July 25, 2014